bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Analysts

Shares of bioMerieux (OTCMKTS:BMXMF) have received a consensus rating of “Reduce” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have assigned a hold recommendation to the company.

Several research firms recently issued reports on BMXMF. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Piper Sandler began coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating on the stock. Finally, Zacks Research raised shares of bioMerieux to a “hold” rating in a research note on Tuesday, April 28th.

bioMerieux Price Performance

Shares of BMXMF stock opened at $80.31 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The firm’s 50 day moving average price is $81.59 and its 200-day moving average price is $100.26. bioMerieux has a one year low of $77.00 and a one year high of $152.00.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.